aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2021-17-4-101-110ateroskleroz-550Research ArticleОБЗОРЫREVIEWSПровоспалительные адипокины и цитокины при абдоминальном ожирении как фактор развития атеросклероза и патологии почекProinflammatory adipokines and cytokines in abdominal obesity as a factor in the development of atherosclerosis and renal pathologyhttps://orcid.org/0000-0001-6884-2237РябоваЕ. А.RyabovaE. A.

Екатерина Александровна Рябова, ординатор 1 года клинической ординатуры по специальности «Терапия»

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Ekaterina A. Ryabova, 1-year resident in the specialty  «Therapy»

630089, Novosibirsk, Boris Bogatkov str., 175/1

catherine.ryabova@yandex.ruhttps://orcid.org/0000-0002-4936-8362РагиноЮ. И.RaginoI. Y.

Юлия Игоревна Рагино, чл.-корр. РАН, д-р мед. наук, проф., руководитель НИИТПМ – филиала ИЦиГ СО РАН

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Yulia I. Ragino, RAS corresponding member, doctor of medical sciences, professor, head of the RIIPM – Branch ICG SB RAS of Internal and Preventive Medicine – Branch of the Federal State Budgetary Institution of Science Federal Research

630089, Novosibirsk, Boris Bogatkov str., 175/1

ragino@mail.ruНаучно-исследовательский институт терапии и профилактической медицины – филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»РоссияResearch Institutе of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of SciencesRussian Federation202113012022174101110Copyright © Рябова Е.А., Рагино Ю.И., 20222022Рябова Е.А., Рагино Ю.И.Ryabova E.A., Ragino I.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/550

В последние десятилетия наблюдается рост распространенности избыточной массы тела и ожирения. Ожирение стало недооцененной пандемией и угрозой общественному здоровью во всем мире. Жировая ткань позиционируется как эндокринный орган, секретирующий широкий спектр провоспалительных цитокинов и адипокинов, индуцируя состояние хронического субвоспаления. Результаты эпидемиологических исследований за последние 30 лет показали также, что висцеральная жировая ткань является независимым фактором риска развития атеросклероза, кардиометаболических заболеваний и хронической болезни почек. Нами выполнен систематический обзор с целью обобщить важные аспекты состояния хронического субвоспаления в контексте его влияния на снижение скорости клубочковой фильтрации и развитие хронической болезни почек. В обзоре рассмотрены вопросы этиологии и патогенеза ожирения, гормонального профиля жировой ткани, молекулярных механизмов воздействия провоспалительных цитокинов и адипокинов на почки и патофизиологии почечных заболеваний. Использованы сведения по теме из публикаций на основе базы данных Pubmed.

In recent decades, there has been an increase in the prevalence of overweight and obesity. Obesity has become an underestimated pandemic and a public health threat around the world. Adipose tissue is positioned as an endocrine organ that secretes a wide range of pro-inflammatory cytokines and adipokines, inducing a state of chronic subinflammation. The results of epidemiological studies over the past 30 years have also shown that visceral adipose tissue is an independent risk factor for the development of atherosclerosis, cardiometabolic diseases and chronic kidney disease. We performed a systematic review to summarize important aspects of the state of chronic subinflammation in the context of its effect on the decrease in glomerular filtration rate and the development of chronic kidney disease. The review deals with the etiology and pathogenesis of obesity, the hormonal profile of adipose tissue, the molecular mechanisms of the effect of pro-inflammatory cytokines and adipokines on the kidneys, and the pathophysiology of renal diseases. Information on the topic from publications based on the Pubmed database has been used.

абдоминальное ожирениеатеросклерозадипокиныцитокиныскорость клубочковой фильтрациихроническое субвоспалениеabdominal obesityatherosclerosisadipokinescytokinesglomerular filtration ratechronic subinflammationРабота проведена в рамках Государственного задания по бюджетной теме НИР № АААА-А17-117112850280-2 и при финансовой поддержке гранта РФФИ 19-013-00800 «Многолетняя динамика избыточной массы тела среди молодых россиян: оценка вклада генетических, поведенческих и социально-экономических факторов в рост распространенности ожирения в России».The work was carried out within the framework of the State Assignment on the budgetary theme of research work No. АААА-А17-117112850280-2 and with the financial support of the RFBR grant 19-013-00800 «Long-term trends of overweight among young Russians: an assessment of the contribution of genetic, behavioral and socio-economic factors to the increase in the prevalence of obesity in Russia.»ReferencesMagalhães D.S.C., Pedro J.M.P., Souteiro P.E.B., Neves J.S., Castro-Oliveira S., Bettencourt-Silva R., Costa M.M., Varela A., Queirós J., Freitas P., Carvalho D. Analyzing the impact of bariatric surgery in kidney function: a 2-year observational study. Obes. Surg., 2019; 29 (1): 197–206. doi:10.1007/s11695-018-3508-1Magalhães D.S.C., Pedro J.M.P., Souteiro P.E.B., Neves J.S., Castro-Oliveira S., Bettencourt-Silva R., Costa M.M., Varela A., Queirós J., Freitas P., Carvalho D. Analyzing the impact of bariatric surgery in kidney function: a 2-year observational study. Obes. Surg., 2019; 29 (1): 197–206. doi:10.1007/s11695-018-3508-1Abella V., Scotece M., Conde J., Pino J., GonzalezGay M.A., Gómez-Reino J.J., Mera A., Lago F., Gomez R., Gualillo O. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat. Rev. Rheumatol., 2017, 13: 100–109. doi:10.1038/nrrheum.2016.209Abella V., Scotece M., Conde J., Pino J., GonzalezGay M.A., Gómez-Reino J.J., Mera A., Lago F., Gomez R., Gualillo O. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat. Rev. Rheumatol., 2017, 13: 100–109. doi:10.1038/nrrheum.2016.209Mihalopoulos N.L., Yap J.T., Beardmore B., Holubkov R., Nanjee M.N., Hoffman J.M. Cold-activated brown adipose tissue is associated with less cardiometabolic dysfunction in young adults with obesity. Obesity, 2020; 28: 916–923. doi:10.1002/oby.22767Mihalopoulos N.L., Yap J.T., Beardmore B., Holubkov R., Nanjee M.N., Hoffman J.M. Cold-activated brown adipose tissue is associated with less cardiometabolic dysfunction in young adults with obesity. Obesity, 2020; 28: 916–923. doi:10.1002/oby.22767Neeland I., Ross R., Després J.-P., Matsuzawa Y., Yamashita S., Shai I., Seidell J., Magni P., Santos R.D., Arsenault B., Cuevas A., Hu F.B., Griffin B., Zambon A., Barter P., Fruchart J.-C., Eckel R.H. International atherosclerosis society; International chair on cardiometabolic risk working group on visceral obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol., 2019; 7 (9): 715–725. doi:10.1016/S2213-8587(19)30084-1Neeland I., Ross R., Després J.-P., Matsuzawa Y., Yamashita S., Shai I., Seidell J., Magni P., Santos R.D., Arsenault B., Cuevas A., Hu F.B., Griffin B., Zambon A., Barter P., Fruchart J.-C., Eckel R.H. International atherosclerosis society; International chair on cardiometabolic risk working group on visceral obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol., 2019; 7 (9): 715–725. doi:10.1016/S2213-8587(19)30084-1Câmara N.O.S., Iseki K., Kramer H., Sharma Z.-H.-L., Sharma K. Kidney disease and obesity: epidemiology, mechanisms and treatment. Nature Reviews. Nephrology, 2017; 13 (3): 181–190. doi:10.1038/nrneph.2016.191Câmara N.O.S., Iseki K., Kramer H., Sharma Z.-H.-L., Sharma K. Kidney disease and obesity: epidemiology, mechanisms and treatment. Nature Reviews. Nephrology, 2017; 13 (3): 181–190. doi:10.1038/nrneph.2016.191The GBD 2015 obesity collaborators: Afshin A., Forouzanfar M.H., Reitsma M.B., Sur P., Estep K., Lee A., Marczak L., Mokdad A.H., Moradi-Lakeh M., Naghavi M., Salama J.S., Vos T., Abate K.H., Abbafati C., Ahmed M.B., Al-Aly Z., Alkerwi A., AlRaddadi R., Amare A.T., Amberbir A., Amegah A.K., Amini E., Amrock S.M., Anjana R.M., Ärnlöv J., Asayesh H., Banerjee A., Barac A., Baye E., Bennett D.A., Beyene A.S., Biadgilign S., Biryukov S., Bjertness E., Boneya D.J., Campos-Nonato I., Carrero J.J., Cecilio P., Cercy K., Ciobanu L.J., Cornaby L., Damtew S.A., Dandona L., Dandona R., Dharmaratne S.D., Duncan B.B., Eshrati B., Esteghamati A., Feigin V.L., Fernandes J.S., Fürst T., Gebrehiwot T., Gold A., Gona P.N., Goto A., Habtewold D.T., Hadush K.T., Hafezi-Nejad N., Hay S.I., Horino M., Islami F., Kamal R., Kasaeian A., Katikireddi S.V., Kengne A.P., Kesavachandran C.N., Khader Y.S., Khang Y.-H., Khubchandani J., Kim D., Kim Y.J., Kinfu Y., Kosen S., Ku T., Defo B.K., Kumar G.A., Larson H.J., Leinsalu M., Liang X., Lim S.S., Liu P., Lopez A.D., Lozano R., Majeed A., Malekzadeh R., Malta D.C., Mazidi M., McAlinden C., McGarvey S.T., Mengistu D.T., Mensah G.A., Mensink G.B.M., Mezgebe H.B., Mirrakhimov E.M., Mueller U.O., Noubiap J.J., Obermeyer C.M., Ogbo F.A., Owolabi M.O., Patton J.C., Pourmalek F., Qorbani M., Rafay A., Rai R.K., Ranabhat C.L., Reinig N., Safiri S., Salomon J.A., Sanabria J.R., Santos I.S., Sartorius B., Sawhney M., Schmidhuber J., Schutte A.E., Schmidt M.I., Sepanlou S.G., Shamsizadeh M., Sheikhbahaei S., Shin M.-J., Shiri R., Shiue I., Roba H.S., Silva D.A.S., Silverberg J.I., Singh J.A., Stranges S., Swaminathan S., Tabarés-Seisdedos R., Tadese F., Tedla B.A., Tegegne B.S., Terkawi A.S., Thakur J.S., Tonelli M., ToporMadry R., Tyrovolas S., Ukwaja K.N., Uthman O.A., Vaezghasemi M., Vasankari T., Vlassov V.V., Vollset S.E., Weiderpass E., Werdecker A., Wesana J., Westerman R., Yano Y., Yonemoto N., Yonga G., Zaidi Z., Zenebe Z.M., Zipkin B., Murray C.J.L. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med., 2017; 377 (1): 13–27. doi:10.1056/NEJMoa1614362The GBD 2015 obesity collaborators: Afshin A., Forouzanfar M.H., Reitsma M.B., Sur P., Estep K., Lee A., Marczak L., Mokdad A.H., Moradi-Lakeh M., Naghavi M., Salama J.S., Vos T., Abate K.H., Abbafati C., Ahmed M.B., Al-Aly Z., Alkerwi A., AlRaddadi R., Amare A.T., Amberbir A., Amegah A.K., Amini E., Amrock S.M., Anjana R.M., Ärnlöv J., Asayesh H., Banerjee A., Barac A., Baye E., Bennett D.A., Beyene A.S., Biadgilign S., Biryukov S., Bjertness E., Boneya D.J., Campos-Nonato I., Carrero J.J., Cecilio P., Cercy K., Ciobanu L.J., Cornaby L., Damtew S.A., Dandona L., Dandona R., Dharmaratne S.D., Duncan B.B., Eshrati B., Esteghamati A., Feigin V.L., Fernandes J.S., Fürst T., Gebrehiwot T., Gold A., Gona P.N., Goto A., Habtewold D.T., Hadush K.T., Hafezi-Nejad N., Hay S.I., Horino M., Islami F., Kamal R., Kasaeian A., Katikireddi S.V., Kengne A.P., Kesavachandran C.N., Khader Y.S., Khang Y.-H., Khubchandani J., Kim D., Kim Y.J., Kinfu Y., Kosen S., Ku T., Defo B.K., Kumar G.A., Larson H.J., Leinsalu M., Liang X., Lim S.S., Liu P., Lopez A.D., Lozano R., Majeed A., Malekzadeh R., Malta D.C., Mazidi M., McAlinden C., McGarvey S.T., Mengistu D.T., Mensah G.A., Mensink G.B.M., Mezgebe H.B., Mirrakhimov E.M., Mueller U.O., Noubiap J.J., Obermeyer C.M., Ogbo F.A., Owolabi M.O., Patton J.C., Pourmalek F., Qorbani M., Rafay A., Rai R.K., Ranabhat C.L., Reinig N., Safiri S., Salomon J.A., Sanabria J.R., Santos I.S., Sartorius B., Sawhney M., Schmidhuber J., Schutte A.E., Schmidt M.I., Sepanlou S.G., Shamsizadeh M., Sheikhbahaei S., Shin M.-J., Shiri R., Shiue I., Roba H.S., Silva D.A.S., Silverberg J.I., Singh J.A., Stranges S., Swaminathan S., Tabarés-Seisdedos R., Tadese F., Tedla B.A., Tegegne B.S., Terkawi A.S., Thakur J.S., Tonelli M., ToporMadry R., Tyrovolas S., Ukwaja K.N., Uthman O.A., Vaezghasemi M., Vasankari T., Vlassov V.V., Vollset S.E., Weiderpass E., Werdecker A., Wesana J., Westerman R., Yano Y., Yonemoto N., Yonga G., Zaidi Z., Zenebe Z.M., Zipkin B., Murray C.J.L. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med., 2017; 377 (1): 13–27. doi:10.1056/NEJMoa1614362Zorena K., Jachimowicz-Duda O., Slezak D., Robakowska M., Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int. J. Mol. Sci., 2020; 21: 3570. doi:10.3390/ijms21103570Zorena K., Jachimowicz-Duda O., Slezak D., Robakowska M., Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int. J. Mol. Sci., 2020; 21: 3570. doi:10.3390/ijms21103570Hetta H.F., Ez-Eldeen M.E., Mohamed G.A., Gaber M.A., ElBadre H.M., Ahmed E.A., Abdellatief R.B., Abd-ElBaky R.M., Elkady A., Nafee A.M. Visfatin serum levels in obese type 2 diabetic patients: relation to proinflammatory cytokines and insulin resistance. Egypt J. Immunol., 2018; 25: 141–151. pmid:30600957Hetta H.F., Ez-Eldeen M.E., Mohamed G.A., Gaber M.A., ElBadre H.M., Ahmed E.A., Abdellatief R.B., Abd-ElBaky R.M., Elkady A., Nafee A.M. Visfatin serum levels in obese type 2 diabetic patients: relation to proinflammatory cytokines and insulin resistance. Egypt J. Immunol., 2018; 25: 141–151. pmid:30600957Fruhbeck G., Kiortsis D.N., Catalan V. Precision medicine: diagnosis and management of obesity. Lancet Diabetes Endocrinol., 2017; 6: 164–166. doi:10.1016/j.mce.2017.04.009Fruhbeck G., Kiortsis D.N., Catalan V. Precision medicine: diagnosis and management of obesity. Lancet Diabetes Endocrinol., 2017; 6: 164–166. doi:10.1016/j.mce.2017.04.009Thyagarajan B., Foster M.T. Beiging of white adipose tissue as a therapeutic strategy for weight loss in humans. Hormone Mol. Biol. and Clin. Investigat., 2017; 16. doi:10.1515/hmbci-2017-0016Thyagarajan B., Foster M.T. Beiging of white adipose tissue as a therapeutic strategy for weight loss in humans. Hormone Mol. Biol. and Clin. Investigat., 2017; 16. doi:10.1515/hmbci-2017-0016Pahlavani M., Kalupahana N.S., Ramalingam L., Moustaid-Moussa N. Regulation and functions of the renin-angiotensin system in white and brown adipose tissue. Comprehensive Physiol., 2017; 7: 1137–1150. doi:10.1002/cphy.c160031Pahlavani M., Kalupahana N.S., Ramalingam L., Moustaid-Moussa N. Regulation and functions of the renin-angiotensin system in white and brown adipose tissue. Comprehensive Physiol., 2017; 7: 1137–1150. doi:10.1002/cphy.c160031Feijóo-Bandín S., Aragón-Herrera A., MorañaFernández S., Anido-Varela L., Tarazón E., Roselló-Lletí E., Portolés M., Moscoso I., Gualillo O., González-Juanatey J.R., Lago F. Adipokines and inflammation: focus on cardiovascular diseases. Int. J. Mol. Sci., 2020; 21: 7711. doi:10.3390/ijms21207711Feijóo-Bandín S., Aragón-Herrera A., MorañaFernández S., Anido-Varela L., Tarazón E., Roselló-Lletí E., Portolés M., Moscoso I., Gualillo O., González-Juanatey J.R., Lago F. Adipokines and inflammation: focus on cardiovascular diseases. Int. J. Mol. Sci., 2020; 21: 7711. doi:10.3390/ijms21207711Horimatsu T., Kim H.W., Weintraub N.L. The role of perivascular adipose tissue in non-atherosclerotic vascular disease. Front. Physiol., 2017; 8: 969. doi:10.3389/fphys.2017.00969Horimatsu T., Kim H.W., Weintraub N.L. The role of perivascular adipose tissue in non-atherosclerotic vascular disease. Front. Physiol., 2017; 8: 969. doi:10.3389/fphys.2017.00969Francisco V., Pino J., Gonzalez-Gay M.A., Mera A., Lago F., Gómez R., Mobasheri A., Gualillo O. Adipokines and inflammation: is it a question of weight? British J. of Pharmacol., 2018; 175: 1569–1579. doi:10.1111/bph.14181Francisco V., Pino J., Gonzalez-Gay M.A., Mera A., Lago F., Gómez R., Mobasheri A., Gualillo O. Adipokines and inflammation: is it a question of weight? British J. of Pharmacol., 2018; 175: 1569–1579. doi:10.1111/bph.14181Ding Y., Xian X., Holland W.L., Tsai S., Herz J. Low-density lipoprotein receptor-related protein-1 protects against hepatic insulin resistance and hepatic steatosis. EBioMedicine, 2016; 7: 135–145. doi:10.1016/j.ebiom.2016.04.002Ding Y., Xian X., Holland W.L., Tsai S., Herz J. Low-density lipoprotein receptor-related protein-1 protects against hepatic insulin resistance and hepatic steatosis. EBioMedicine, 2016; 7: 135–145. doi:10.1016/j.ebiom.2016.04.002Rebecchi F., Allaix M.E., Patti M.G., Schlottmann F., Morino M. Gastroesophageal reflux disease and morbid obesity: to sleeve or not to sleeve? World J. Gastroenterol., 2017; 23 (13): 2269–2275. doi:10.3748/wjg.v23.i13.2269Rebecchi F., Allaix M.E., Patti M.G., Schlottmann F., Morino M. Gastroesophageal reflux disease and morbid obesity: to sleeve or not to sleeve? World J. Gastroenterol., 2017; 23 (13): 2269–2275. doi:10.3748/wjg.v23.i13.2269Villarroya F., Cereijo R., Gavaldà-Navarro A., Villarroya J., Giralt M. Inflammation of brown/beige adipose tissues in obesity and metabolic disease. J. Intern. Med., 2018; 284: 492–504. doi:10.1111/joim.12803Villarroya F., Cereijo R., Gavaldà-Navarro A., Villarroya J., Giralt M. Inflammation of brown/beige adipose tissues in obesity and metabolic disease. J. Intern. Med., 2018; 284: 492–504. doi:10.1111/joim.12803Rodriguez A., Becerril S., Ezquerro S., MendezGimenez L., Fruhbeck G. Cross-talk between adipokines and myokines in fat browning. Acta Physiol., 2017; 219: 362–381. doi:10.1111/apha.12686Rodriguez A., Becerril S., Ezquerro S., MendezGimenez L., Fruhbeck G. Cross-talk between adipokines and myokines in fat browning. Acta Physiol., 2017; 219: 362–381. doi:10.1111/apha.12686Bateman A., Cheung S.T., Bennett H.P.J. A brief overview of progranulin in health and disease. Methods in Mol. Biol., 2018. doi:10.1007/978-1-4939-8559-3_1Bateman A., Cheung S.T., Bennett H.P.J. A brief overview of progranulin in health and disease. Methods in Mol. Biol., 2018. doi:10.1007/978-1-4939-8559-3_1Favre G., Anty R., Canivet C. Determinants associated with the correction of glomerular hyper-filtration one year after bariatric surgery. Surg. Obes. Relat. Dis., 2017; 13 (10): 1760–1766. doi:10.1016/j.soard.2017.07.018Favre G., Anty R., Canivet C. Determinants associated with the correction of glomerular hyper-filtration one year after bariatric surgery. Surg. Obes. Relat. Dis., 2017; 13 (10): 1760–1766. doi:10.1016/j.soard.2017.07.018Abella V., Pino J., Scotece M., Conde J., Lago F., Gonzalez-Gay M.A. Progranulin as a biomarker and potential therapeutic agent. Drug Discov. Today, 2017; 22: 1557–1564. doi:10.1016/j.drudis.2017.06.006Abella V., Pino J., Scotece M., Conde J., Lago F., Gonzalez-Gay M.A. Progranulin as a biomarker and potential therapeutic agent. Drug Discov. Today, 2017; 22: 1557–1564. doi:10.1016/j.drudis.2017.06.006Cebeci E., Çakan C., Gursu M., Uzun S., Karada G.S., Kolda S.M., Çalhan T., Helvaci S.A., Öztürk S. The main determinants of serum resistin level in type 2 diabetic patients are renal function and inflammation not presence of microvascular complication, obesity and insulin resistance. Exp. Clin. Endocrinol. Diabetes, 2018; 127: 189–194. doi:10.1055/s-0043-121262Cebeci E., Çakan C., Gursu M., Uzun S., Karada G.S., Kolda S.M., Çalhan T., Helvaci S.A., Öztürk S. The main determinants of serum resistin level in type 2 diabetic patients are renal function and inflammation not presence of microvascular complication, obesity and insulin resistance. Exp. Clin. Endocrinol. Diabetes, 2018; 127: 189–194. doi:10.1055/s-0043-121262Lynch M., Ahern T., Sweeney C.M., Malara A., Tobin A.M., O’Shea D., Kirby B. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int. J. Dermatol., 2017; 56 (11): 1103–1118. doi:10.1111/ijd.13699Lynch M., Ahern T., Sweeney C.M., Malara A., Tobin A.M., O’Shea D., Kirby B. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int. J. Dermatol., 2017; 56 (11): 1103–1118. doi:10.1111/ijd.13699Davis F.M., Gallagher K.A. Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease. Arterioscler. Thromb. Vasc. Biol., 2019; 39 (4): 623–634. doi:10.1161/ATVBAHA.118.312135Davis F.M., Gallagher K.A. Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease. Arterioscler. Thromb. Vasc. Biol., 2019; 39 (4): 623–634. doi:10.1161/ATVBAHA.118.312135Konaniah E.S., Kuhel D.G., Basford J.E., Weintraub N.L., Hui D.Y. Deficiency of LRP1 in mature adipocytes promotes diet-induced inflammation and atherosclerosis–brief report. Arteriosclerosis, Thrombosis, and Vascular. Biol., 2017; 37 (6): 1046–1049. doi:10.1161/ATVBAHA.117.309414Konaniah E.S., Kuhel D.G., Basford J.E., Weintraub N.L., Hui D.Y. Deficiency of LRP1 in mature adipocytes promotes diet-induced inflammation and atherosclerosis–brief report. Arteriosclerosis, Thrombosis, and Vascular. Biol., 2017; 37 (6): 1046–1049. doi:10.1161/ATVBAHA.117.309414Recinella L., Orlando G., Ferrante C., Chiavaroli A., Brunetti L. Leone S. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front. Physiol., 2020; 11. doi:10.3389/fphys.2020.578966Recinella L., Orlando G., Ferrante C., Chiavaroli A., Brunetti L. Leone S. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front. Physiol., 2020; 11. doi:10.3389/fphys.2020.578966Djudjaja S., Boora P. Cellular and molecular mechanisms of kidney fibrosis. Mol. Aspects of Medicine, 2018; 6. doi:10.1016/j.mam.2018.06.002Djudjaja S., Boora P. Cellular and molecular mechanisms of kidney fibrosis. Mol. Aspects of Medicine, 2018; 6. doi:10.1016/j.mam.2018.06.002Lu C.-C., Wang G.-H., Lu J., Chen P.-P., Zhang Y., Hu Z.-B., Ma K.-L. Role of podocyte injury in glomerulosclerosis. Renal Fibrosis: Mechanisms and Therapies, Adv. Exp. Med. Biol., 2019; 1165: 195–232. doi:10.1007/978-981-13-8871-2_10Lu C.-C., Wang G.-H., Lu J., Chen P.-P., Zhang Y., Hu Z.-B., Ma K.-L. Role of podocyte injury in glomerulosclerosis. Renal Fibrosis: Mechanisms and Therapies, Adv. Exp. Med. Biol., 2019; 1165: 195–232. doi:10.1007/978-981-13-8871-2_10Dumas D.L.R.C. Actualite´ sur les me´ canismes physiopathologiques des syndromes ne´phrotiques idiopathiques: le´ sions glome´ rulaires minimes et hyalinose segmentaire et focale. Ne´phrol. Ther., 2018; 14 (7). doi:10.1016/j.nephro.2018.06.001Dumas D.L.R.C. Actualite´ sur les me´ canismes physiopathologiques des syndromes ne´phrotiques idiopathiques: le´ sions glome´ rulaires minimes et hyalinose segmentaire et focale. Ne´phrol. Ther., 2018; 14 (7). doi:10.1016/j.nephro.2018.06.001Rayego-Mateos S., Valdivielso J.M. New therapeutic targets in chronic kidney disease progression and renal fibrosis. Expert Opinion on Therapeutic Targets, 2020. doi:10.1080/14728222.2020.1762173Rayego-Mateos S., Valdivielso J.M. New therapeutic targets in chronic kidney disease progression and renal fibrosis. Expert Opinion on Therapeutic Targets, 2020. doi:10.1080/14728222.2020.1762173Nogueira A., Pires M.J., Oliviera P.A. Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In vivo, 2017; 31: 1–22. doi:10.21873/invivo.11019Nogueira A., Pires M.J., Oliviera P.A. Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In vivo, 2017; 31: 1–22. doi:10.21873/invivo.11019Wakamatsu K., Seki Y., Kasama K., Uno K., Hashimoto K., Seto Y., Kurokawa Y. Prevalence of chronic kidney disease in morbidly obese Japanese and the impact of bariatric surgery on disease progression. Obesity Surgery, 2017. doi:10.1007/s11695-017-2863-7Wakamatsu K., Seki Y., Kasama K., Uno K., Hashimoto K., Seto Y., Kurokawa Y. Prevalence of chronic kidney disease in morbidly obese Japanese and the impact of bariatric surgery on disease progression. Obesity Surgery, 2017. doi:10.1007/s11695-017-2863-7Favre G. Longitudinal assessment of renal function in native kidney after bariatric surgery. Surgery for Obesity and Related Diseases, 2018. doi:10.1016/j.soard.2018.05.013Favre G. Longitudinal assessment of renal function in native kidney after bariatric surgery. Surgery for Obesity and Related Diseases, 2018. doi:10.1016/j.soard.2018.05.013Park H.K., Kwak M.K., Kim H.J., Ahima R.S. Linking resistin, inflammation, and cardiometabolic diseases. Korean J. Intern. Med., 2017; 32: 239–247. doi:10.3904/kjim.2016.229Park H.K., Kwak M.K., Kim H.J., Ahima R.S. Linking resistin, inflammation, and cardiometabolic diseases. Korean J. Intern. Med., 2017; 32: 239–247. doi:10.3904/kjim.2016.229Andrade-Oliveira V., Foresto-Neto O., Watanabe I.K.M. Inflammation in renal diseases: new and old players. Front. Pharmacol., 2019; 10: 1192. doi:10.3389/fphar.2019.01192Andrade-Oliveira V., Foresto-Neto O., Watanabe I.K.M. Inflammation in renal diseases: new and old players. Front. Pharmacol., 2019; 10: 1192. doi:10.3389/fphar.2019.01192Zeng L.F., Xiao Y., Sun L. A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy. Adv. Exp. Med. Biol., 2019; 1165: 49–79. doi:10.1007/978-981-13-8871-2_4Zeng L.F., Xiao Y., Sun L. A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy. Adv. Exp. Med. Biol., 2019; 1165: 49–79. doi:10.1007/978-981-13-8871-2_4Chang A.R., Grams M.E., Navaneethan S.D. Bariatric surgery and kidney-related outcomes. Kidney Int. Rep., 2017; 2 (2): 261–270. doi:10.1016/j.ekir.2017.01.010Chang A.R., Grams M.E., Navaneethan S.D. Bariatric surgery and kidney-related outcomes. Kidney Int. Rep., 2017; 2 (2): 261–270. doi:10.1016/j.ekir.2017.01.010Orellana J.M., Kampe K., Schulze F., Sieber J., Jehle A.W. Fetuin-A aggravates lipotoxicity in podocytes via interleukin-1 signaling. Physiol. Rep., 2017; 5. doi:10.14814/phy2.13287Orellana J.M., Kampe K., Schulze F., Sieber J., Jehle A.W. Fetuin-A aggravates lipotoxicity in podocytes via interleukin-1 signaling. Physiol. Rep., 2017; 5. doi:10.14814/phy2.13287Wilson P.C., Kashgarian M., Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin. Kidney J., 2018; 11 (2): 207–218. doi: 10.1093/ckj/sfx093Wilson P.C., Kashgarian M., Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin. Kidney J., 2018; 11 (2): 207–218. doi: 10.1093/ckj/sfx093Gu Y.-Y., Liu X.-S., Huang X.-R., Yu X.-Q., Lan H.-Y. TGF-β in renal fibrosis: triumphs and challenges. Future Med. Chem., 2020; 12 (9): 853–866. doi:10.4155/fmc-2020-0005Gu Y.-Y., Liu X.-S., Huang X.-R., Yu X.-Q., Lan H.-Y. TGF-β in renal fibrosis: triumphs and challenges. Future Med. Chem., 2020; 12 (9): 853–866. doi:10.4155/fmc-2020-0005Choi S.Y., Lim S.W., Salimi S., Yoo E.J., LeeKwon W., Lee H.H. Tonicity-responsive enhancerbinding protein mediates hyperglycemia-induced inflammation and vascular and renal injury. J. Am. Soc. Nephrol., 2018; 29: 492–504. doi:10.1681/ASN.2017070718Choi S.Y., Lim S.W., Salimi S., Yoo E.J., LeeKwon W., Lee H.H. Tonicity-responsive enhancerbinding protein mediates hyperglycemia-induced inflammation and vascular and renal injury. J. Am. Soc. Nephrol., 2018; 29: 492–504. doi:10.1681/ASN.2017070718Nosalski R., Guzik T.J. Perivascular adipose tissue inflammation in vascular disease. British J. Pharmacol., 2017; 174: 3496–3513. doi:10.1111/bph.13705Nosalski R., Guzik T.J. Perivascular adipose tissue inflammation in vascular disease. British J. Pharmacol., 2017; 174: 3496–3513. doi:10.1111/bph.13705Nehus E. Obesity and chronic kidney disease. Curr. Opin. Pediatr., 2018; 30. doi:10.1097/MOP.0000000000000586Nehus E. Obesity and chronic kidney disease. Curr. Opin. Pediatr., 2018; 30. doi:10.1097/MOP.0000000000000586Mehta N., Gava A.L., Zhang D. Follistatin protects against glomerular mesangial cell apoptosis and oxidative stress to ameliorate chronic kidney disease. Antioxid Redox Signal, 2019; 31: 551–571. doi:10.1089/ars.2018.7684Mehta N., Gava A.L., Zhang D. Follistatin protects against glomerular mesangial cell apoptosis and oxidative stress to ameliorate chronic kidney disease. Antioxid Redox Signal, 2019; 31: 551–571. doi:10.1089/ars.2018.7684Gaillard M., Tranchart H., Beaudreuil S., Lebrun A., Voican C.S., Lainas P., Courie R., Perlemuter G., Parier B., Hammoudi Y., Durrbach A., Dagher I. Laparoscopic sleeve gastrectomy for morbid obesity in renal transplantation candidates: a matched case–control study. Transplant International, 2020; 33: 1061– 1070. doi:10.1111/tri.13637Gaillard M., Tranchart H., Beaudreuil S., Lebrun A., Voican C.S., Lainas P., Courie R., Perlemuter G., Parier B., Hammoudi Y., Durrbach A., Dagher I. Laparoscopic sleeve gastrectomy for morbid obesity in renal transplantation candidates: a matched case–control study. Transplant International, 2020; 33: 1061– 1070. doi:10.1111/tri.13637Aggarwal H.K., Jain D., Chauda R., Bhatia S., Sehgal R. Assessment of malnutrition inflammation score in different stages of chronic kidney disease. Pril. (Makedon. Akad. Nauk. Umet. Odd. Med. Nauk.), 2018; 39: 51–61. doi:10.2478/prilozi-2018-0042Aggarwal H.K., Jain D., Chauda R., Bhatia S., Sehgal R. Assessment of malnutrition inflammation score in different stages of chronic kidney disease. Pril. (Makedon. Akad. Nauk. Umet. Odd. Med. Nauk.), 2018; 39: 51–61. doi:10.2478/prilozi-2018-0042Lin Y.-C., Lai Y.-J., Lin Y.-C., Peng C.-C., Chen K.- C., Chuang M.-T., Wu M.-S., Chang T.-H. Effect of weight loss on the estimated glomerular filtration rates of obese patients at risk of chronic kidney disease: the RIGOR-TMU study. J. Cachexia, Sarcopenia and Muscle, 2019. doi:10.1002/jcsm.12423Lin Y.-C., Lai Y.-J., Lin Y.-C., Peng C.-C., Chen K.- C., Chuang M.-T., Wu M.-S., Chang T.-H. Effect of weight loss on the estimated glomerular filtration rates of obese patients at risk of chronic kidney disease: the RIGOR-TMU study. J. Cachexia, Sarcopenia and Muscle, 2019. doi:10.1002/jcsm.12423Liu M., Ning X., Li R. Signalling pathways involved in hypoxia-induced renal fibrosis. J. Cell. Mol. Med., 2017; 21 (7): 1248–1259. doi:10.1111/jcmm.13060Liu M., Ning X., Li R. Signalling pathways involved in hypoxia-induced renal fibrosis. J. Cell. Mol. Med., 2017; 21 (7): 1248–1259. doi:10.1111/jcmm.13060

The authors declare that there are no conflicts of interest present.